Sign in
Taking peopleNo phase

Development of a Multidimensional Prediction Model for the Course and Outcome of Early-Onset Juvenile Idiopathic Arthritis (JIA)

Key facts

Who runs it
Istituto Giannina Gaslini
Where
Italy2 sites in 1 countryChoose a country to see its sites
Trial code
Status
Recruiting
People taking part
130 people, planned
Started
30 Jul 2024
Expected to end
31 Dec 2028
Type of study
Observational, 2 groups
Record updated
20 October 2026

Who can take part

Age
2 years to 17 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 5 criteriaShow less

Who can take part

  • For patients with JIA; A diagnosis of JIA according to the ILAR criteria by the treating pediatric rheumatologist; Classification in one of the following ILAR JIA categories: oJIA, RF-pJIA, PsA, or undifferentiated arthritis; Age < 6 years at onset; Onset of JIA symptoms no more than 6 months before enrolment; Duly executed, written, informed consent/assent obtained from the parents/patient; For control subjects
  • A diagnosis of Iridocyclitis not correlated to JIA by the treating pediatric ophtalmologist
  • Age ≤ 17 years at diagnosis
  • Duly executed, written, informed consent/assent obtained from the parents/patient

Who cannot take part

  • For patients with JIA; Classification in one of the following ILAR JIA categories: systemic arthritis, RF-positive polyarthritis, enthesitis-related arthritis; Previous treatment with any synthetic or biologic DMARD before biologic sample collection; For control subjects; ● Previous treatment with any synthetic or biologic DMARD before biologic sample collection

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 2 and 17 years old?

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

This is a prospective-retrospective, translational, no profit, multicentric, observational study. A cohort of at least 100 early-onset JIA patients attending the Unit of Rheumatology and Autoinflammatory Diseases, Department of Pediatric Sciences, IRCCS Istituto Giannina Gaslini or selected Italian pediatric rheumatology centers, will be enrolled and evaluated at onset and at 5 time points of follow up to 24 months (month 3, month 6, month 12, month 18 and month 24) to monitor the course of the disease. A cohort of 30 patients with Iridocyclitis not correlated to JIA will be recruited in parallel at the time of disease diagnosis as a group of control for comparison.

The 2 groups in the trial

  • Early-onset JIA patients

    Early-onset Juvenile Idiopathic Arthritis (JIA) represents the most common form of arthritis in Western country, affecting the 70-80% of Italian children. It typically occurs before the age of 6, has female predilection, high frequency of positive antinuclear antibodies (ANA),and is characterized by a high risk (20-30% of cases) of chronic iridocyclitis

  • Iridocyclitis patients not correlated to JIA

    Group of control for comparison.

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Fit questions
Built from NCT07882667, who can take part
Record updated
20 October 2026
Development of a Multidimensional Prediction Model for the Course and Outcome of Early-Onset Juvenile Idiopathic Arthritis (JIA) (NCT07882667) – Frontlight Research